Serum and mucosal antibody responses and protection in pigs vaccinated against Mycoplasma hyopneumoniae with vaccines containing a denatured membrane antigen pool and adjuvant.
OBJECTIVE
To investigate the protective efficacy of a pool of denatured membrane protein antigens of Mycoplasma hyopneumoniae (J strain) in the molecular size range 70 to 85 kDa (F3 antigen) in combination with adjuvants for pigs challenged with M hyopneumoniae.


METHODS
A vaccine efficacy experiment with assessment of serum and respiratory tract antibody responses.


METHODS
F3 antigens were emulsified with five different adjuvants. To groups of three pigs per vaccine, four vaccines were given by intramuscular injection, and two vaccines, including one of those given intramuscularly, were given by intraperitoneal injection.


RESULTS
Compared to six unvaccinated pigs, animals vaccinated with F3 antigen displayed significantly reduced pneumonia (54% reduction in mean lung score) following experimental challenge. Analysis of post-vaccination, pre-challenge IgG and IgA ELISA antibody absorbances in serum and respiratory tract washings revealed no correlation with lung score. Six weeks after challenge, pigs previously vaccinated intramuscularly mostly demonstrated greater IgG and IgA responses in respiratory tract washings, and greater IgG serum antibody responses, than those vaccinated by intraperitoneal injection.


CONCLUSIONS
Pigs vaccinated with M hyponeumoniae antigens in the molecular size range of 70 to 85 kDa showed a significant reduction in lung lesions compared with unvaccinated control animals after experimental challenge. IgG and IgA antibody concentrations in serum and respiratory tract washings after vaccination do not provide a useful prognostic indicator of protection from enzootic pneumonia.
Djordjevic
S P
SP
NSW Agriculture, Elizabeth Macarthur Agricultural Institute, Camden, New South Wales.
Eamens
G J
GJ
Romalis
L F
LF
Nicholls
P J
PJ
Taylor
V
V
Chin
J
J
D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000818:Animals; D000907:Antibodies, Bacterial / Q000032:analysis / Q000096:biosynthesis* / Q000097:blood; D000942:Antigens, Bacterial / Q000008:administration & dosage / Q000276:immunology; D001428:Bacterial Vaccines / Q000008:administration & dosage / Q000276:immunology*; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods / Q000662:veterinary; D007070:Immunoglobulin A / Q000032:analysis / Q000096:biosynthesis / Q000097:blood; D007074:Immunoglobulin G / Q000032:analysis / Q000096:biosynthesis / Q000097:blood; D015994:Incidence; D007273:Injections, Intramuscular / Q000379:methods / Q000662:veterinary; D007274:Injections, Intraperitoneal / Q000379:methods / Q000662:veterinary; D008565:Membrane Proteins / Q000008:administration & dosage / Q000276:immunology; D008970:Molecular Weight; D009092:Mucous Membrane / Q000737:chemistry / Q000276:immunology / Q000473:pathology; D009174:Mycoplasma / Q000276:immunology*; D045729:Pneumonia of Swine, Mycoplasmal / Q000276:immunology / Q000517:prevention & control / Q000662:veterinary*; D011379:Prognosis; D012137:Respiratory System / Q000737:chemistry / Q000276:immunology / Q000473:pathology; D013552:Swine; D013553:Swine Diseases / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control*; D014611:Vaccination / Q000379:methods / Q000662:veterinary*
D000276:Adjuvants, Immunologic; D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; D001428:Bacterial Vaccines; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D008565:Membrane Proteins